Ads
related to: new prostate cancer drugs- Clinical Trial Data
View Clinical Data & Results
From a Pivotal Trial for XTANDI®
- XTANDI® FAQs For HCPs
Explore FAQs for Providers & Better
Prepare Your Patients.
- Treatment Guidelines
Review NCCN and AUA Guidelines That
Support the Use of XTANDI®.
- Mechanism of Disease
Disease Information & Implications
Of Treatment with XTANDI®
- Clinical Trial Data
Search results
Results from the WOW.Com Content Network
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according to a new study.
New York, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain. Prostate cancer is one of the most common cancers among men worldwide, especially in aging populations.
Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant ...
The candidate, JANX007, reduced prostate-specific (PSA) antigen levels in a majority of the 23 patients who received the drug, the company said late on Monday, adding that deeper reductions were ...
Ads
related to: new prostate cancer drugs